Lumretuzumab Overview

Introduction of Lumretuzumab

Lumretuzumab is a humanized and glycoengineered anti-HER3 therapeutic monoclonal antibody that inhibits HER3 signaling and induces antibody-dependent cellular cytotoxicity of tumor cells due to a glycoengineered antibody Fc moiety. This antibody was developed by Roche and has been investigated in the trials studying the treatment of many cancers such as neoplasms, breast cancer, squamous non-small cell lung cancer, and non-squamous non-small cell lung cancer. The most recent study on lumretuzumab is the evaluation of the safety and clinical activity of lumretuzumab combined with anti-HER2 antibody pertuzumab and paclitaxel in the treatment of HER3-positive, HER2 low-metastatic breast cancer. The results of this phase Ib trial showed a high incidence of diarrhea treated with lumizumab, pertuzumab, and paclitaxel, and changing the dose cannot guarantee its safety in clinical treatment. Subsequently, a model of combined treatment was established to describe the occurrence and severity of diarrhoea and to provide information on how the severity of key adverse events evolved over time. The role of lumretuzumab in cancer treatment remains to be studied.

Mechanism of Action of Lumretuzumab

HER3, also known as Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3), is a member of the human epidermal receptor family. Like other members of his ERBB family, HER3 is also made up of three different domains, extracellular ligand binding domain (ECD), transmembrane region (TM) and intracellular tyrosine kinase binding domain (ICD). The amplification and over-representation of HER3 have been found in a number of malignant tumors, including breast cancer, gastric cancer, bladder cancer, ovarian cancer, prostate cancer, colorectal cancer, head and neck squamous cell carcinoma and melanoma. The involvement of HER3 in tumorigenesis and development may be due to its unique ability to directly initiate the PI3K/AKT pathway. PI3K/AKT pathway is the most important signaling pathway to promote the proliferation of tumor cells. It is also involved in the regulation of gene expression, cell metabolism, cytoskeleton rearrangement and so on. In addition, a number of studies have confirmed that HER2-HER3 dimer plays a key role in the occurrence and development of human tumors. In tumors with overexpression of HER2, HER3 is a necessary companion for HER2 to play an important role in tumorigenesis. Therefore, anti-HER2 and anti-HER3 antibodies are usually used in combination in the treatment of tumors. The mechanism of lumretuzumab in tumor treatment is to kill tumor cells by inhibiting the HER3 signaling pathway and antibody-dependent cell cytotoxicity.

Fig 1. Mechanism of Action of Lumretuzumab

What We Provide

Therapeutic Antibody

Lumretuzumab

We provide high-quality Lumretuzumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

For research use only. Not intended for any clinical use.